Evidence Explorer / Evidence record

MS-N013 · Literature searched October 13, 2026 · Appraised October 13, 2026 · Fatigue

Evidence at a glance

• Direct negative trial: 236 women with newly diagnosed breast cancer beginning adjuvant chemotherapy were randomized to CoQ10 300 mg/day or placebo; both groups received vitamin E 300 IU/day for 24 weeks.
• Primary result: fatigue measured with POMS-F and FACIT-F did not improve with CoQ10; quality of life and depression were also similar.
• Exposure check: plasma CoQ10 rose substantially, arguing against simple failure to absorb the supplement.
• Newer signal: a 2026 single-center open-label trial randomized 60 women receiving weekly paclitaxel to usual treatment with or without ubiquinol 400 mg/day. Fatigue was a secondary toxicity outcome, not the primary endpoint.
• Bottom line: current evidence does not establish CoQ10 as a dependable cancer-fatigue treatment.

What was studied?

Population and treatment: The larger trial enrolled women starting adjuvant chemotherapy for breast cancer. The 2026 trial enrolled a narrower weekly-paclitaxel population and excluded several higher-risk groups, including people with metastatic disease, diabetes and chronic kidney disease.

Formulation and duration: The blinded trial used 300 mg/day of oral CoQ10 plus vitamin E for 24 weeks; the placebo group also received vitamin E. The 2026 trial used ubiquinol 200 mg twice daily for 12 weeks. These are study regimens, not personal dosing advice.

Endpoints: Fatigue was central in the larger blinded trial. In the 2026 study, the primary endpoint was grade 2 or worse paclitaxel neuropathy; fatigue was one of several clinician-graded secondary toxicities. No cancer-control endpoint was tested.

How to read the conflicting results

The older study is larger, blinded and directly designed around self-reported fatigue, and it was negative. The newer result is worth tracking but is small, open label and tested many toxicity outcomes without a placebo. Expectation and observer effects can influence fatigue grading, especially late in treatment. A broad 2022 meta-analysis found less fatigue across mixed noncancer and cancer populations, but indirect evidence should not overrule the best direct trial in the target setting.

Safety and practical context

CoQ10 is often tolerated, but gastrointestinal symptoms and insomnia can occur. NCCIH notes possible interactions with warfarin and insulin and cautions that compatibility with some cancer treatments is uncertain. Antioxidant supplementation during chemotherapy also raises a treatment-interaction question that the fatigue trials were not designed to settle. Persistent fatigue still deserves evaluation for anemia, infection, thyroid or adrenal problems, sleep disruption, pain, depression, medication effects and inadequate nutrition.

Funding and conflicts: Funding and conflict details for the 2012 trial and the 2026 trial were not fully reverified in this pass; consult the original reports before a formal evidence synthesis. The 2022 meta-analysis reported one author as founder of InnovaRad Inc.

Questions for the care team

• What reversible causes of fatigue have been checked?
• Could CoQ10 interact with chemotherapy, warfarin, insulin or other medicines?
• What outcome would we track, and when would we stop if there is no clear benefit?
• Which guideline-supported fatigue interventions fit the treatment and functional level?

Sources

• Lesser et al., randomized double-blind trial — PMID 22682875; NCT00096356
• ClinicalTrials.gov results — NCT00096356
• 2026 open-label paclitaxel trial — PMID 42401951; DOI 10.1186/s40360-026-01163-7
• 2022 fatigue meta-analysis — PMID 36091835
• NCCIH CoQ10 safety overview — checked October 13, 2026

Learn how to judge a study · Return to the evidence map

This evidence brief is educational, not a personal treatment recommendation. Research regimens are not prescribing instructions. Symptom benefit does not establish tumor response, recurrence prevention or survival benefit.